Literature DB >> 11530870

The effect of antenatal corticosteroid therapy on pregnancies complicated by premature rupture of membranes.

H S Qublan, H Y Malkawi, M S Hiasat, I M Hindawi, M I Al-Taani, S A Abu-Khait, J F Al-Maaitah.   

Abstract

UNLABELLED: This study was carried out to examine the effect of antenatal corticosteroid therapy on pregnancies complicated by premature rupture of membranes (PROMs). For this purpose, 139 patients with a singleton pregnancy (27-34 weeks of gestation) complicated by PROMs were evaluated prospectively during the period January 1997 to February 1999 at two Jordanian military hospitals (Prince Rhashed and Prince Zaid). Patients were allocated into two groups; Group 1 included 72 patients treated with dexamethsone (24 mg divided into 4 doses 12 hours apart), and Group 2 which included 67 patients whoreceived no treatment (control group). All women were examined clinically and the diagnosis of PROMs was demonstrated using vaginal speculum, nitrazine paper examination and ultrasonography. All neonates were evaluated clinically, radiologically, and by laboratory investigations. Pearson's Chi-square and Fisher's exact tests were used to assess the significance of differences between the two study groups. Respiratory distress syndrome (RDS), necrotizing enterocolitis (NEC), intraventricular haemorrhage (IVH), and days of hospital stay were significantly reduced in premature infants of the corticosteroid treated women compared with the controls (p<0.04, p<0.04, p<0.04, and p<0.05, respectively). The perinatal mortality was significantly decreased among the corticosteroid treated group in the gestational subgroups 31-32 and 33-34 weeks (p<0.04), and in all birth weight subgroups (p<0.03). RDS was statistically a significant factor which resulted in increased perinatal mortality in the control group (p=0.02). Regarding the occurrence of postpartum endometritis there was a statistically significant increase among the corticosteroid treated group compared with the controls (p<0.04).
CONCLUSION: Antenatal corticosteroid therapy in pregnancies complicated by PROMs has a positive influencing effect on premature infants between 31 and 34 weeks of gestation, decreasing significantly the perinatal morbidity and mortality. It should be used with particular relevance to the developing world where surfactant is not available or where neonatal intensive care units are lacking.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11530870

Source DB:  PubMed          Journal:  Clin Exp Obstet Gynecol        ISSN: 0390-6663            Impact factor:   0.146


  7 in total

1.  A conference report on prenatal corticosteroid use in low- and middle-income countries.

Authors:  Elizabeth M McClure; Joseph de Graft-Johnson; Alan H Jobe; Steve Wall; Marge Koblinsky; Allisyn Moran; Linda L Wright; Winifride Mwebesa; Marion Koso-Thomas; Robert L Goldenberg
Journal:  Int J Gynaecol Obstet       Date:  2011-09-17       Impact factor: 3.561

Review 2.  Antenatal steroids in preterm labour for the prevention of neonatal deaths due to complications of preterm birth.

Authors:  Judith Mwansa-Kambafwile; Simon Cousens; Thomas Hansen; Joy E Lawn
Journal:  Int J Epidemiol       Date:  2010-04       Impact factor: 7.196

Review 3.  Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth.

Authors:  Devender Roberts; Julie Brown; Nancy Medley; Stuart R Dalziel
Journal:  Cochrane Database Syst Rev       Date:  2017-03-21

Review 4.  Antenatal corticosteroids for women at risk of imminent preterm birth in low-resource countries: the case for equipoise and the need for efficacy trials.

Authors:  Joshua P Vogel; Olufemi T Oladapo; Cynthia Pileggi-Castro; Ebunoluwa A Adejuyigbe; Fernando Althabe; Shabina Ariff; Adejumoke Idowu Ayede; Abdullah H Baqui; Anthony Costello; Davy M Chikamata; Caroline Crowther; Bukola Fawole; Luz Gibbons; Alan H Jobe; Monica Lulu Kapasa; John Kinuthia; Alka Kriplani; Oluwafemi Kuti; James Neilson; Janna Patterson; Gilda Piaggio; Rahat Qureshi; Zahida Qureshi; Mari Jeeva Sankar; Jeffrey S A Stringer; Marleen Temmerman; Khalid Yunis; Rajiv Bahl; A Metin Gülmezoglu
Journal:  BMJ Glob Health       Date:  2017-08-30

5.  Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth.

Authors:  Emma McGoldrick; Fiona Stewart; Roses Parker; Stuart R Dalziel
Journal:  Cochrane Database Syst Rev       Date:  2020-12-25

Review 6.  Born too soon: care during pregnancy and childbirth to reduce preterm deliveries and improve health outcomes of the preterm baby.

Authors:  Jennifer Requejo; Mario Merialdi; Fernando Althabe; Matthais Keller; Joanne Katz; Ramkumar Menon
Journal:  Reprod Health       Date:  2013-11-25       Impact factor: 3.223

7.  Antenatal Dexamethasone for Early Preterm Birth in Low-Resource Countries.

Authors:  Olufemi T Oladapo; Joshua P Vogel; Gilda Piaggio; My-Huong Nguyen; Fernando Althabe; A Metin Gülmezoglu; Rajiv Bahl; Suman P N Rao; Ayesha De Costa; Shuchita Gupta; Abdullah H Baqui; Rasheda Khanam; Mohammod Shahidullah; Saleha B Chowdhury; Salahuddin Ahmed; Nazma Begum; Arunangshu D Roy; M A Shahed; Iffat A Jaben; Farida Yasmin; M Mozibur Rahman; Anjuman Ara; Soofia Khatoon; Gulshan Ara; Shaheen Akter; Nasreen Akhter; Probhat R Dey; M Abdus Sabur; Mohammad T Azad; Shahana F Choudhury; M A Matin; Shivaprasad S Goudar; Sangappa M Dhaded; Mrityunjay C Metgud; Yeshita V Pujar; Manjunath S Somannavar; Sunil S Vernekar; Veena R Herekar; Shailaja R Bidri; Sangamesh S Mathapati; Preeti G Patil; Mallanagouda M Patil; Muttappa R Gudadinni; Hidaytullah R Bijapure; Ashalata A Mallapur; Geetanjali M Katageri; Sumangala B Chikkamath; Bhuvaneshwari C Yelamali; Ramesh R Pol; Sujata S Misra; Leena Das; Saumya Nanda; Rashmita B Nayak; Bipsa Singh; Zahida Qureshi; Fredrick Were; Alfred Osoti; George Gwako; Ahmed Laving; John Kinuthia; Hafsa Mohamed; Nawal Aliyan; Adelaide Barassa; Elizabeth Kibaru; Margaret Mbuga; Lydia Thuranira; Njoroge J Githua; Bernadine Lusweti; Adejumoke I Ayede; Adegoke G Falade; Olubukola A Adesina; Atinuke M Agunloye; Oluwatosin O Iyiola; Wilfred Sanni; Ifeyinwa K Ejinkeonye; Hadiza A Idris; Chinyere V Okoli; Theresa A Irinyenikan; Omolayo A Olubosede; Olaseinde Bello; Olufemi M Omololu; Olanike A Olutekunbi; Adesina L Akintan; Olorunfemi O Owa; Rosena O Oluwafemi; Ireti P Eniowo; Adetokunbo O Fabamwo; Elizabeth A Disu; Joy O Agbara; Ebunoluwa A Adejuyigbe; Oluwafemi Kuti; Henry C Anyabolu; Ibraheem O Awowole; Akintunde O Fehintola; Bankole P Kuti; Anthony D Isah; Eyinade K Olateju; Olusanya Abiodun; Olabisi F Dedeke; Francis B Akinkunmi; Lawal Oyeneyin; Omotayo Adesiyun; Hadijat O Raji; Adedapo B A Ande; Ikechukwu Okonkwo; Shabina Ariff; Sajid B Soofi; Lumaan Sheikh; Saima Zulfiqar; Sadia Omer; Raheel Sikandar; Salma Sheikh; Daniel Giordano; Hugo Gamerro; Guillermo Carroli; Jose Carvalho; James Neilson; Elizabeth Molyneux; Khalid Yunis; Kidza Mugerwa; Harish K Chellani
Journal:  N Engl J Med       Date:  2020-10-23       Impact factor: 91.245

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.